05-611
Anti-phospho-VASP (Ser239) Antibody, clone 16C2
clone 16C2, Upstate®, from mouse
Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
About This Item
Codice UNSPSC:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Prodotti consigliati
Origine biologica
mouse
Livello qualitativo
Forma dell’anticorpo
purified immunoglobulin
Tipo di anticorpo
primary antibodies
Clone
16C2, monoclonal
Reattività contro le specie
mouse, rat, human
Produttore/marchio commerciale
Upstate®
tecniche
flow cytometry: suitable
immunocytochemistry: suitable
western blot: suitable
Isotipo
IgG1κ
N° accesso NCBI
N° accesso UniProt
Condizioni di spedizione
wet ice
modifica post-traduzionali bersaglio
phosphorylation (pSer239)
Informazioni sul gene
human ... VASP(7408)
Specificità
Based on sequence homology this antibody is also predicted to cross-react with dog and cow.
phosphorylated VASP
Immunogeno
phospho-peptide corresponding to amino acids 236-242 of human phospho-VASP (RKV[pS]KQE)
Applicazioni
Research Category
Signaling
Signaling
Research Sub Category
Cytoskeletal Signaling
Cytoskeletal Signaling
This Anti-phospho-VASP (Ser239) Antibody, clone 16C2 is validated for use in FC, WB, IC for the detection of phospho-VASP (Ser239).
Qualità
routinely evaluated by immunoblot on RIPA lysates from CTLL cells
Descrizione del bersaglio
50kDa
Stato fisico
100µg of mouse IgG1 from serum-free cell culture supernatant, purified by thiophilic adsorption and size exclusion chromatography. Lyophilized from 1ml of PBS, 0.1% sodium azide, PEG and sucrose. Lyophilized powder. Reconstitute with 100 µL H2O (15 min, RT) for a final concentration of 1 mg/mL. Store at -20°C.
Format: Purified
Thiophilic adsorption chromatography
Stoccaggio e stabilità
2 years at -20°C
Note legali
UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany
Esclusione di responsabilità
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Non trovi il prodotto giusto?
Prova il nostro Motore di ricerca dei prodotti.
Codice della classe di stoccaggio
10 - Combustible liquids
Certificati d'analisi (COA)
Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.
Possiedi già questo prodotto?
I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.
Insulin stimulates glucose transport via nitric oxide/cyclic GMP pathway in human vascular smooth muscle cells.
Bergandi, L; Silvagno, F; Russo, I; Riganti, C; Anfossi, G; Aldieri, E; Ghigo, D; Trovati et al.
Arteriosclerosis, Thrombosis, and Vascular Biology null
I Kishimoto et al.
Journal of neuroendocrinology, 20(11), 1213-1223 (2008-08-30)
Cyclic GMP (cGMP) is known to play important roles for neuronal development and neurite pathfinding. However, the regulatory mechanism that governs the synthesis of cGMP in the nervous system is not well defined. In the present study, we examined the
A Mülsch et al.
Circulation, 103(17), 2188-2194 (2001-05-23)
Chronic in vivo treatment with nitroglycerin (NTG) induces tolerance to nitrates and cross-tolerance to nitrovasodilators and endothelium-derived nitric oxide (NO). We previously identified increased vascular superoxide formation and reduced NO bioavailability as one causal mechanism. It is still controversial whether
Eberhard Schulz et al.
Circulation, 105(10), 1170-1175 (2002-03-13)
In experimental animal models, long-term in vivo treatment with nitroglycerin (NTG) induces both endothelial dysfunction and tolerance to nitrates. However, it is still controversial whether nitrate tolerance in humans is associated with both endothelial dysfunction and impaired vascular response to
Jonel Trebicka et al.
Hepatology (Baltimore, Md.), 47(4), 1264-1276 (2008-03-06)
In cirrhosis, splanchnic vasodilation contributes to portal hypertension, subsequent renal sodium retention, and formation of ascites. Urotensin II(U-II) is a constrictor of large conductive vessels. Conversely, it relaxes mesenteric vessels, decreases glomerular filtration, and increases renal sodium retention. In patients
Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..
Contatta l'Assistenza Tecnica.